| Select Book Parts: |
21 CFR 3 - Product Jurisdiction |
| |
21 CFR 7 - Enforcement Policy |
| |
21 CFR 11 - Electronic Records with Scope and Application |
| |
21 CFR 11 - Electronic Records with Computerized Systems used in Clinical Investigations |
| |
21 CFR 11 - Electronic Records with Scope and Application and Preambles |
| |
21 CFR 11 - Electronic Records with Part 11 Checklist |
| |
21 CFR 11 - Electronic Records - Spanish Translation |
| |
21 CFR 13 - Public Hearing |
| |
21 CFR 16 - Regulatory hearing before the Food and Drug Administration |
| |
21 CFR 50 - Protection of Human Subjects |
| |
21 CFR 54 - Financial Disclosure by Clinical Investigators |
| |
21 CFR 56 - Institutional Review Boards |
| |
21 CFR 58 - Good Laboratory Practice |
| |
21 CFR 101 - Food Labeling |
| |
21 CFR 106 - Infant Formula Quality Control Procedures |
| |
21 CFR 107 - Infant Formula |
| |
21 CFR 108 - Emergency Permit Control |
| |
21 CFR 110 - Current Good Manufacturing Practice, in Manufacturing, Packing, or Holding Human Food |
| |
21 CFR 110 - Food GMPs - Spanish Translation |
| |
21 CFR 111 - Dietary Supplement handbook |
| |
21 CFR 113 - Thermally Processed Low-Acid FoodsS Packaged in Hermetically Sealed Containers |
| |
21 CFR 114 - Acidified Foods |
| |
21 CFR 115 - Shell Eggs |
| |
21 CFR 118 - Production, Storage, and Transportation of Shell Eggs |
| |
21 CFR 120 - Hazard Analysis and Critical Control Point (HACCP) Systems |
| |
21 CFR 123 - Fish and Fishery Products |
| |
21 CFR 130 - Food standards: General |
| |
21 CFR 131 - Milk and Cream |
| |
21 CFR 133 - Cheeses and Related Cheese Products |
| |
|
| |
21 CFR 200 - General Drug |
| |
21 CFR 201 - Drug Labeling |
| |
21 CFR 203 - Prescription Drug Marketing |
| |
21 CFR 205 - Guidelines for State Licensing of Wholesale Prescription Drug Distributors |
| |
21 CFR 210/211 - Drug GMPs 210 cGMP Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General - 211 cGMP for Finished Pharmaceuticals |
| |
21 CFR 210/211 - Drug GMPs - Spanish Translation |
| |
21 CFR 210/211 - with Drug Preambles |
| |
21 CFR 210/211 - with GMP Audit Check List |
| |
21 CFR 210/211 - with Keyword Index |
| |
21 CFR 312 - Investigational New Drug Application |
| |
21 CFR 314 - Applications for FDA Approval to Market a New Drug |
| |
21 CFR 316 - Orphan Drugs |
| |
21 CFR 511 - New Animal Drugs For Investigational Use |
| |
21 CFR 600 - Biological Products: General |
| |
21 CFR 601 - Licensing - Biologics |
| |
21 CFR 606 - Current Good Manufacturing Practice, for Blood and Blood Components |
| |
21 CFR 607 - Establishment Registration and Product Listing for Manufacturers of Human Blood and Blood Products |
| |
21 CFR 610 - General Biological Products Standards |
| |
21 CFR 630 - General Requirements for Blood, Blood Components, and Blood Derivatives |
| |
21 CFR 640 - Additional Standards for Human Blood and Blood Products |
| |
21 CFR 660 - Additional Standards for Diagnostic Substances for Laboratory Tests |
| |
21 CFR 680 - Additional Standards for Miscellaneous Products |
| |
21 CFR 700 - Cosmetic-General |
| |
21 CFR 701 - Cosmetic-Labeling |
| |
Cosmetic - Is It Soap or a Drug |
| |
21 CFR 801 - Labeling - Medical Device |
| |
21 CFR 803 - Medical Device Reporting |
| |
21 CFR 806 - Medical Devices; Reports of Corrections and Removal |
| |
21 CFR 807 - Establishment Registration and Device Listing for Manufacturers and Initial Importers of Devices |
| |
21 CFR 809 - In-Vitro Diagnostic Products |
| |
21 CFR 810 - Medical Device Recall Authority |
| |
21 CFR 812 - Investigational Device Exemptions |
| |
21 CFR 814 - Premarket Approval of Medical Device |
| |
21 CFR 820 - Quality System Regulations |
| |
21 CFR 820 - with Quality System Regulations (QSR) Audit Checklist |
| |
21 CFR 820 - Quality System Regulations - Spanish Translation |
| |
21 CFR 820 - Quality System Regulations - Chinese Translation |
| |
21 CFR 821 - Medical Device Tracking Requirements |
| |
21 CFR 822 - Postmarket Surveillance |
| |
21 CFR 1270 - Human Tissue Intended for Transplantation |
| |
21 CFR 1271 - Human Cells, Tissues, and Cellular and Tissue Based Products |
| |
40 CFR 160 - Good Laboratory Practice Standards |
| |
42 CFR 493 - Laboratory Requirements |
| |
45 CFR 46 - Protection of Human Subjects |
| |
45 CFR 160 - General Administrative Requirements |
| |
45 CFR 162 - Administrative Requirements |
| |
EU GMPs - Chapter 1 - 9 |
| |
Annex 1 Manufacture of Sterile Medicinal Products |
| |
Annex 2 Manufacture of Biological Medical Products for Human Use |
| |
Annex 3 Manufacture of Radiopharmaceuticals |
| |
Annex 4 Manufacture of Veterinary Medical Products Other than Immunological Veterinary Medical Products |
| |
Annex 5 Manufacture of Immunological Veterinary Medical Products |
| |
Annex 6 Manufacture of Medicinal Gases |
| |
Annex 7 Manufacture of Herbal Medicinal Products |
| |
Annex 8 Sampling of Starting and Packaging Materials |
| |
Annex 9 Manufacture of Liquids, Creams and Ointments |
| |
Annex 10 Inhalation Products |
| |
Annex 11 Computerized Systems |
| |
Annex 12 Ionizing Radiation |
| |
Annex 13 Investigational medicinal Products |
| |
Annex 14 Human Blood or Plasma Products |
| |
Annex 15 Qualification and Validation |
| |
Annex 16 Qualified Person and Batch Release |
| |
Annex 17 Parametric Release |
| |
Annex 19 Reference and Retention Samples |
| |
Annex 20 Quality Risk Management |
| |
ICH E2A - Clinical Safety Data Management: Definitions and Standards for Expedited Reporting |
| |
ICH E4 - Dose-Response Information to Support Drug Registration |
| |
ICH E6 - Good Clinical Practice |
| |
ICH E8 - General Considerations for Clinical Trials |
| |
ICH M3(R2) - Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals |
| |
ICH Q1A(R2) - Stability Testing of New Drug Substances and Products |
| |
ICH Q1B - Stability Testing: Photostability Testing of New Drug Substances and Products |
| |
ICH Q1C - Stability Testing for new Dosage Forms |
| |
ICH Q1E - Evaluation of Stability Data |
| |
ICH Q2(R1) - Validation of Analytical Procedures: Test and Methodology |
| |
ICH Q3A(R2) - Impurities in New Substances |
| |
ICH Q3B(R2) - Impurities in New Products |
| |
ICH Q3C(R5) - Impurities: Guideline for Residual Solvents |
| |
ICH Q5A(R1) - Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human and Animal Origin |
| |
ICH Q5B - Analysis of the Expression Construct in Cell Usage for Production of r-DNA Derived Protein Products |
| |
ICH Q5C - Stability Testing of Biotechnological / Biological Products |
| |
ICH Q5D - Derivation and Characterisation of Cell Substrates Used for Products of Biotechnological / Biological Products |
| |
ICH Q5E - Comparability of Biotechnological / Biological Products Subject to Changes in their Manufacturing Process |
| |
ICH Q6A - Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances |
| |
ICH Q6B - Specifications: Test Procedures and Acceptance Criteria Biotechnological / Biological Products |
| |
ICH Q7 - Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients |
| |
ICH Q8(R2) - Pharmaceutical Development |
| |
ICH Q9 - Quality Risk Management |
| |
ICH Q10 - Pharmaceutical Quality System |
| |
ICH Q8/9/10 (R4) - Questions and Answers |
| |
ICH S2(R1) - Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use |
| |
ICH S6 - Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals |
| |
ICH S7A - Safety Pharmacology Studies for Human Pharmaceuticals |
| |
Pharmaceutical CGMPS for the 21st Century - A RISK-BASED APPROACH |
| |
Computerized Systems Used in Clinical Investigations |
| |
Guideline on General Principles of Process Validation |
| |
Definition of a Combination Product |
| |
Compliance Program Guidance Manual for FDA Staff |
| |
Inspection of Medical Device Manufacturers Document issued on: June 15, 2006 Program 7382.845 |
| |
GMP - PAT Handbook |
| |
93/42/EEC Medical Device Directive |
| |
Drug Manufacturing Inspections |
| |
Program 7356.002 |
| |
Canadian GMP - Good Manufacturing Practices (GMP) Guidelines 2009 EDITION GUI-0001 |
| |
Canadian GCP - Drugs for Clinical Trials Involving Human Subjects |
| |
Canadian - Annex 2 to the Current Edition of the GMP Guidelines: Manufacture of Drugs Used in Clinical Trials |
| |
Canadian - SOR/98-282 Medical Devices Regulations |
| |
Japanese GMP for Drugs and Quasi-drugs - 2005 |
| |
EU Clinical Trials Directive |
| |
Medical Device Quality Systems Manuel |
| |
Medical Device Reporting for Manufacturers |
| |
OECD General Principal 1 |
| |
PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance |
| |
Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing Practice |
| |
General Principles of Software Validation |
| |
Quality Systems Approach to Pharmaceutical CGMP Regulations |
| |
Medical Device QSIT Manual |
| |
Pharmacovigilance for Medical Products Volume 9a |
| |
PMA Premarket Approval |
| |
510k Guidelines |
| |
| Comments: |
|
| |
|
